Capricor Therapeutics (CAPR) News Today

Capricor Therapeutics, Inc. (NASDAQ: CAPR) remains under pressure as investors assess concerns surrounding clinical-trial disclosures and a wave of securities-fraud class-action announcements. The legal notices appear to be a consequence of the sharp selloff rather than new operating developments, but they add reputational, litigation and potential financial risks.

• Positive Sentiment: An analyst reportedly increased the fair-value outlook for Capricor’s lead asset, deramiocel, following revisions to the product’s outlook. This provides some potential support for the company’s underlying pipeline valuation, although it has been overshadowed by the recent data controversy. Capricor Therapeutics Stock Gets Fair Value Boost After Deramiocel Analyst Revisions
• Neutral Sentiment: Multiple law firms, including Kaplan Fox, Bleichmar Fonti & Auld, Pomerantz, Rosen and Hagens Berman, are soliciting investors to serve as lead plaintiffs in securities class actions covering purchases generally made from December 17, 2025, through July 26, 2026. The notices repeat allegations that Capricor and certain executives violated federal securities laws; the claims have not been proven. Lead-plaintiff deadlines are primarily September 28, with some notices citing September 29. Kaplan Fox Urges Investors to Seek a Leadership Role
• Negative Sentiment: The key market concern is an alleged discrepancy in FDA briefing documents involving unagreed changes to the HOPE-3 statistical analysis plan. Reports say the revelations raised questions about clinical-data integrity and contributed to Capricor shares plunging as much as 64% to 78.7%. The resulting lawsuits and investor-alert campaign increase uncertainty around regulatory review, potential liability and the credibility of the company’s clinical disclosures. SueWallSt Reminds Investors of Pending Class Action